|
|
Article: Biomira Completes Enrolment of BLP25 Liposomal Vaccine Phase IIB Study in Non-Small Cell Lung Cancer.
- Article from:
- PR Newswire
- Article date:
- November 13, 2002
CopyrightCOPYRIGHT 2002 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Biomira Inc. (TSX: BRA) announced today that the Company has completed enrolment of the planned 166 patients in its Phase IIb clinical trial with BLP25 Liposomal vaccine. There are now 168 patients enrolled into the trial. The controlled, randomized study involves patients with advanced non-small cell lung cancer (NSCLC) and enrolment was conducted at 13 sites in Canada and four in the United Kingdom. The trial began in August 2000. Final recruitment in the trial has been extended to allow a few previously identified patients the opportunity to be included in the trial. Enrolment for these identified patients is expected to close later this month.
Since the ...